Bicara Therapeutics (NASDAQ:BCAX) Upgraded at Guggenheim

Bicara Therapeutics (NASDAQ:BCAX) was upgraded by stock analysts at Guggenheim to a “strong-buy” rating in a note issued to investors on Sunday,Zacks.com reports.

Several other equities analysts also recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Wednesday, April 8th. HC Wainwright raised their price target on Bicara Therapeutics from $40.00 to $42.00 and gave the company a “buy” rating in a report on Tuesday, March 31st. The Goldman Sachs Group raised their price target on Bicara Therapeutics from $14.00 to $16.00 and gave the company a “neutral” rating in a report on Tuesday, March 31st. BTIG Research reaffirmed a “buy” rating on shares of Bicara Therapeutics in a report on Thursday, January 15th. Finally, Citizens Jmp reaffirmed a “market outperform” rating and set a $31.00 price target on shares of Bicara Therapeutics in a report on Tuesday, March 31st. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $29.40.

Bicara Therapeutics Stock Up 1.5%

BCAX opened at $22.92 on Friday. The firm has a market capitalization of $1.50 billion, a P/E ratio of -9.06 and a beta of -0.57. The stock’s 50 day moving average price is $20.74 and its two-hundred day moving average price is $18.08. Bicara Therapeutics has a 12-month low of $7.80 and a 12-month high of $24.25.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.29). As a group, analysts anticipate that Bicara Therapeutics will post -2.72 earnings per share for the current year.

Insider Transactions at Bicara Therapeutics

In other news, COO Ryan Cohlhepp sold 12,500 shares of the business’s stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $23.01, for a total value of $287,625.00. Following the sale, the chief operating officer directly owned 196,141 shares in the company, valued at $4,513,204.41. The trade was a 5.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Claire Mazumdar sold 15,000 shares of the business’s stock in a transaction dated Monday, April 20th. The shares were sold at an average price of $23.61, for a total value of $354,150.00. Following the completion of the sale, the chief executive officer owned 362,152 shares in the company, valued at approximately $8,550,408.72. This trade represents a 3.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 174,310 shares of company stock valued at $3,459,283.

Institutional Trading of Bicara Therapeutics

A number of institutional investors have recently modified their holdings of BCAX. T. Rowe Price Investment Management Inc. raised its holdings in Bicara Therapeutics by 596.5% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,236,595 shares of the company’s stock worth $54,472,000 after acquiring an additional 2,771,868 shares in the last quarter. Janus Henderson Group PLC bought a new stake in Bicara Therapeutics during the fourth quarter worth about $44,484,000. Vestal Point Capital LP raised its holdings in Bicara Therapeutics by 80.6% during the second quarter. Vestal Point Capital LP now owns 5,000,000 shares of the company’s stock worth $46,450,000 after acquiring an additional 2,231,025 shares in the last quarter. Franklin Resources Inc. bought a new stake in Bicara Therapeutics during the fourth quarter worth about $27,265,000. Finally, State Street Corp raised its holdings in Bicara Therapeutics by 179.5% during the fourth quarter. State Street Corp now owns 1,649,537 shares of the company’s stock worth $27,762,000 after acquiring an additional 1,059,260 shares in the last quarter.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.